# Coherus Oncology, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Coherus Oncology, Inc.). ## Overview Coherus Oncology, Inc. is a U.S.-based commercial-stage oncology company focused on proprietary immuno-oncology medicines. Its core business is the commercialization of LOQTORZI (toripalimab-tpzi) and the advancement of mid-stage pipeline candidates aimed at overcoming immune resistance in cancer. ## Products & services • LOQTORZI (toripalimab-tpzi) commercial oncology therapy • Casdozokitug clinical-stage immuno-oncology candidate • CHS-114 clinical-stage oncology candidate • Tagmokitug preclinical/early-stage immuno-oncology asset • Development and commercialization rights in the U.S. and Canada - **Commercial oncology product** (70%) — Approved immuno-oncology therapy sold in the United States and supported by partner commercialization in Canada. - **Clinical-stage pipeline** (20%) — Mid-stage and early-stage oncology candidates being developed for additional cancer indications and combinations. - **Licensing and collaboration rights** (10%) — Exclusive regional rights, options, and milestone/royalty arrangements tied to toripalimab and related assets. - LOQTORZI (toripalimab-tpzi) approved PD-1 inhibitor for oncology - Casdozokitug mid-stage candidate for solid tumors - CHS-114 oncology pipeline candidate - Tagmokitug immuno-oncology pipeline asset - U.S. and Canada commercialization rights and partnering - Contract manufacturing and clinical supply management ## Customers The company sells primarily into the oncology treatment ecosystem, where prescribing physicians, hospitals, integrated delivery networks, and managed care organizations determine adoption and reimbursement. Demand is driven by clinical efficacy, safety, guideline placement, and payer coverage, rather than direct consumer choice. In Canada, commercialization is supported through a partner license arrangement, while the U.S. business is directly commercialized. - **Oncology prescribers** (primary) — Medical oncologists and treatment centers that prescribe LOQTORZI based on efficacy, safety, and label fit. - **Hospitals and cancer networks** (primary) — Hospitals, integrated delivery networks, and cancer centers that decide formulary inclusion and treatment pathways. - **Payers and reimbursement gatekeepers** (primary) — Government and commercial payers that determine coverage and patient access for oncology biologics. - **Strategic partners** (secondary) — License and collaboration partners that help commercialize or develop assets in selected territories. - Oncologists prescribing LOQTORZI for approved cancer indications - Hospitals and cancer centers that add therapies to formularies - Integrated delivery networks seeking reimbursable oncology options - Managed care and government payers influencing access and coverage - Commercial partners in Canada supporting regional launch ## Geography Coherus Oncology primarily operates in the United States and measures its business as one reportable segment centered there. It also has a Canada commercialization arrangement for toripalimab, but the company states that it operates primarily in the U.S. and partners for other countries. Management is also executing a manufacturing onshoring initiative to bring production of LOQTORZI, casdozokitug, and tagmokitug to the United States. - United States is the core commercial and operating market - Canada is addressed through a licensing/partner model - Other countries are served mainly through partners, not direct ops - Biomanufacturing is being onshored to the United States - U.S. concentration increases exposure to domestic pricing and reimbursement ## Strategy The company’s strategy is to build LOQTORZI sales in nasopharyngeal carcinoma while expanding into new indications and combination regimens. It is also repositioning as a pure-play immuno-oncology company after divesting its biosimilar businesses and is working to strengthen supply chain control by onshoring manufacturing. - **Expand LOQTORZI commercialization** (short-term) — The approved product is the main revenue engine and the base for future indication expansion. - **Advance pipeline candidates** (medium-term) — Pipeline success is needed to diversify revenue and support long-term growth beyond one marketed product. - **Strengthen manufacturing control** (medium-term) — Reducing dependence on third-party CMOs can improve supply security and commercial readiness. - Grow LOQTORZI sales in NPC and broaden label opportunities - Advance casdozokitug and CHS-114 through clinical development - Use combination regimens to improve differentiation and uptake - Focus the company on proprietary immuno-oncology after divestitures - Onshore manufacturing to improve supply reliability and control ## Risks The business is highly dependent on a single approved product and on successful clinical, regulatory, and commercial execution for its pipeline. It also faces intense competition from larger oncology companies, payer pressure, and manufacturing/supply chain dependence on third parties. Because the company is still building scale after divesting its biosimilar businesses, funding needs and execution risk remain elevated. - **Dependence on LOQTORZI** [high] — The company has only one approved commercial product, so any launch, safety, or reimbursement setback would materially affect revenue. - **Clinical and regulatory failure of pipeline assets** [high] — Casdozokitug, CHS-114, and other candidates are still in development and may never reach approval. - **Competitive pressure in immuno-oncology** [high] — LOQTORZI competes with entrenched PD-1/PD-L1 therapies from much larger companies with stronger commercial resources. - **Manufacturing and supply chain reliance** [medium] — The company relies on CMOs for commercial and clinical supply, which can create delays, quality issues, or cost inflation. - **Payer and pricing pressure** [high] — Coverage, formulary placement, and state/federal drug pricing rules can limit access and net pricing. - Single-product dependence makes revenue vulnerable to launch or uptake issues - Pipeline candidates may fail in clinical trials or regulatory review - Large oncology competitors can limit market share and pricing power - Third-party manufacturing creates supply and quality risk - Payer coverage and drug pricing pressure can restrict adoption ## Accounting Investors should watch revenue recognition for product sales and collaboration/royalty arrangements, since the company’s economics include both direct sales and partner-related payments. The company also has meaningful judgment areas around product sales discounts and allowances, fair value changes on discontinued operations, and estimates tied to development-stage assets and contingent obligations. Because it has undergone major divestitures, discontinued operations presentation can materially affect comparability across periods. - **Product sales discounts and allowances** — Can materially change reported product revenue and margins - **Collaboration royalties and milestones** — Affects gross margin and operating cash requirements - **Discontinued operations** — Can distort trend analysis across years - **Fair value measurements** — Can introduce earnings volatility unrelated to core operations - Product sales net of discounts and allowances affect reported net revenue - Royalty and milestone arrangements can create timing and estimate risk - Discontinued operations presentation affects comparability after biosimilar divestitures - Fair value changes on liabilities can create non-operating volatility - Development-stage estimates and contingencies rely on management judgment --- *Last updated: 2026-04-28T19:58:35.376457+00:00*